Empowering Biotech Startups: The Advantages Of Non-Dilutive Funding

Over the past year, biotech startups have encountered difficulties in raising capital, with fewer IPOs and more selective venture capital and private equity investments. In light of these challenges, startups need to seek alternative funding options beyond traditional methods like mergers and acquisitions.

Organizations like the National Institutes of Health and the Cancer Prevention & Research Institute of Texas (CPRIT) offer valuable grant opportunities that can be aligned with contract development and manufacturing organizations (CDMOs) to support clinical trials. These opportunities, commonly referred to as non-dilutive funding, enable companies to finance clinical manufacturing without sacrificing equity. Over the years, non-dilutive funding has become more available in the life sciences field due to significant government interest in promoting public health initiatives. Since many funding programs have strict timelines, it’s important to establish CDMO partnerships early to ensure efficient and timely production.

Read on to learn more about non-dilutive funding opportunities and how early CDMO collaboration can streamline clinical manufacturing in today’s competitive funding environment.